Neurophysiological Correlates of Dissociation Induced by Virtual Reality Hypnosis.

July 4, 2023 updated by: Audrey Vanhaudenhuyse, University of Liege

Neurophysiological Correlates of Dissociation Induced by Virtual Reality Hypnosis (VRH) and Hypnosis (HYP) in a Healthy Participants.

Hypnosis and virtual reality are potential tools in treating acute pain. Nevertheless, the neurophysiological correlates of such tools used together, i.e. 'virtual reality hypnosis' (VRH) (Patterson et al., 2004) remain mostly understudied. This study aims to improve our knowledge and understanding of the dissociation (i.e., a mental separation of components of behaviours that normally would be processed together) occurring during VRH. This is a randomized controlled study that will be conducted on healthy participants. As the final goal is to propose such a tool in the clinical context, a clinical application will also be carried out subsequently.

Thus the principal outcome is to study dissociation in the context of VRH from a behavioral and neurophysiological point of view.

Secondary objectives aim at identifying factors that influence the dissociative effect seen in VRH, as well as measuring traits of hypnotisability, absorption, immersive abilities, dissociation trait and state, pain, and anxiety levels that might impact the effectiveness of such a tool.

Study Overview

Detailed Description

The protocol will follow the following steps:

  1. Before the experiment:

    • A medical screening of the medical history and of any concomitant medications will be performed to eligibility.
    • The 6-item Elkins Hypnotisability Scale (EHS) will be used to assess participant hypnotisability.
    • Questionnaire sur la Propension à l'Immersion (QPI) will be used to assess participant immersion tendency.
  2. Experimental session: Cross-over and within-participant control design i. Visual Analogue Scale (VAS) :

    • Anxiety.
    • Pain. ii. EEG Resting-state (5-Min.). iii. EEG VRH or EEG Hypnosis alone (HYP) (15-Min.). iv. Adverse Events (AE) during the protocol will be recorded. v. Narrative recording. vi. VAS :
    • Dissociation
    • Absorption
    • Pain
    • Anxiety
    • Arousal/wakefulness
    • Automaticity vii. Time perception (open question) viii. CyberSickness (CSQ) (only if VRH) ix. Presence Questionnaire x. Satisfaction questionnaire xi. Washout Phase (30-Min.) during which we will administer :
    • Six-item State-Trait Anxiety Inventory (STAI-6) .
    • Tellegen Absorption Scale .
    • Dissociative Experience Scales (DES) . xii. VAS:
    • Anxiety
    • Pain xiv. Adverse Events during the protocol will be recorded. xv. Narrative recording. xvi. EEG HYP or EEG VRH Phase (15-Min.). xvii. VAS:
    • Dissociation
    • Absorption
    • Pain
    • Anxiety
    • Arousal/wakefulness
    • Time perception xviii. CSQ (only if VRH) xix. Presence Questionnaire. xx. Satisfaction Questionnaire .

Study Type

Interventional

Enrollment (Actual)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Liège, Belgium, 4000
        • Chu of Liège

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria: Subject more than 18 years old and equal or less than 65 years old.

Exclusion Criteria:

  1. Low auditory and/or visual acuity precludes the use of the device.
  2. Head or face wounds precluding the use of the device.
  3. Schizophrenia, dissociative disorder or any other psychiatric disorder.
  4. Non-proficiency in French (Research language).
  5. Patient under 18 years old.
  6. Phobia of deep water.
  7. Allergy to cutaneous electrodes.
  8. Chronic pain and/or chronic analgesics consumption.
  9. Medication affecting the autonomic nervous system.
  10. Dizziness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Healthy Volunteers - Hypnosis without VR (HYP )
Cross-over and within-participant control design: Participants will receive recorded hypnosis without VR.
HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script "Heaven of Peace" developped/recorded by Pr. M-E. Faymonville will be used.
Experimental: Healthy Volunteers - Hypnosis with VR (VRH)
Cross-over and within-participant control design: Participants will receive hypnosis with VR.
The VRH intervention will use the Aqua video session developed by Oncomfort.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dissociation state
Time Frame: During the procedure
Corresponds to a dissociation between the bodily sensations and the actual environment that one feels in a particular situation. will be assessed with a numerical rating scale (0= no dissociation; 10 = dissociation from environment).
During the procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain intensity
Time Frame: During the procedure
The amount of pain one experiences in a particular situation. Will be assessed with a visual analogy scale, 0= no pain at all; 10= worst pain imaginable.
During the procedure
Dissociation trait
Time Frame: During the procedure
The amount of dissociation one experiences in one's daily life. Will be assessed with the Dissociative Experience Scale, the higher the score, the more one experiences dissociation in one's daily life.
During the procedure
Absorption trait
Time Frame: During the procedure
The tendency to become fully involved in a perceptual, imaginative or ideational experience. Will be assessed with the Tellegen Absorption Scale, the higher the score the higher the absorption in the daily life.
During the procedure
Immersion propensity (trait)
Time Frame: During the procedure
Immersion propensity is the amount of sensory input the virtual reality system creates. Will be assessed with the Immersion Propensity questionnaire. The higher the score, the more one is immersed in the virtual environments.
During the procedure
Anxiety state
Time Frame: During the procedure
The amount of anxiety one experiences in a particular situation. Will be assessed with a visual analogy scale. a score = 0 means no anxiety at all, while a score = 10 means most anxiety ever felt.
During the procedure
Automaticity
Time Frame: During the procedure
A non-voluntary response related to the content of a communication that is intended to be a suggestion. Will be assessed with a numerical rating scale : 0= perfect control; 10 = passive witness.
During the procedure
Time perception
Time Frame: During the procedure
Open-ended question about one's impression of the duration of the VHR and HYP sessions.
During the procedure
Cybersickness
Time Frame: During the procedure
Assesses the sickness one might experience after the VRH. Will be assessed with the Cybersickness questionnaire. The higher the score, the more one has experience sickness during the VRH.
During the procedure
Presence
Time Frame: During the procedure
Refers to the degree to which the subject experiences being in the virtual environment. Will be assessed with the presence questionnaire, the higher the score the higher one has the feeling of really being in the virtual environment.
During the procedure
Satisfaction of the participant
Time Frame: During the procedure
Assesses the overall satisfaction one has had with the VRH and HYP session. Will be assessed by a self-made satisfaction questionnaire, the higher the score, the more one is satisfied with the experience.
During the procedure
Hypnotisability
Time Frame: During the procedure

The susceptibility one has concerning hypnosis. Will be assessed with the Elkins Hypnotizability Scale.

A score :

0-3 : low hypnotizability 4-7: medium hypnotizability 8-11 : high hypnotizability 12 : very high hypnotizability

During the procedure
Anxiety trait
Time Frame: During the procedure
Level of anxiety one experiences in one's daily life. Will be assessed with the STAI-6 questionnaire. The higher the score, the higher the anxiety one feels in one's daily life.
During the procedure
Absorption state
Time Frame: During the procedure
The amount of absroption one experiences in a particular situation. Will be assessed with a numercial rating scale, 0 = no absorption; 10 = fully absorption by the experience.
During the procedure
Arousal/wakefulness
Time Frame: During the procedure
The amount of arousal one experiences in a particular situation. Will be assessed with a visual analogy scale, 0=not aroused, awaked; 10 = completely aroused, awake.
During the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Audrey VANHAUDENHUYSE, PhD, Chu of Liège

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 8, 2022

Primary Completion (Actual)

June 14, 2023

Study Completion (Actual)

June 14, 2023

Study Registration Dates

First Submitted

April 11, 2022

First Submitted That Met QC Criteria

April 26, 2022

First Posted (Actual)

May 2, 2022

Study Record Updates

Last Update Posted (Actual)

July 6, 2023

Last Update Submitted That Met QC Criteria

July 4, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • QuDDoS - Phase-I

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteers

Clinical Trials on Hypnosis without VR (HYP)

Subscribe